Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of …

Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of …

The trial enrolled patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was PFS

(Visited 2 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.